Therapeutic stem cell nutrient composition and uses thereof

Abstract

The present invention relates to a composition and uses thereof for treatment of damaged tissue comprising at least one essential amino acid in L form and at least one essential lipid; wherein the composition is administered to a mammal suffering from severe tissue damage. The invention further relates to a composition and uses thereof comprising the mixture of one or more free L-amino acids in which the molar ratio of the free L-amino acids corresponds to the molar ratio of amino components in a mammalian tissue protein; and at least one essential lipid.

1 . A method of treating damaged tissue, comprising administering an anabolic composition to a subject in need of such treatment, wherein the anabolic composition comprises: a) at least one extracellular matrix compound in an amount effective in the damaged tissue as anti-inflammatory and anti-neo-angiogenic agent, b) at least one polar surface active lipid; and c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of human breast milk protein, and wherein no more than 10% of the amino acids are in D-form. 
     
     
         2 . The method of  claim 1 , wherein the extracellular matrix compound is synthetically produced. 
     
     
         3 . The method of  claim 1 , wherein the extracellular matrix compound is obtained from a cellular or tissue source. 
     
     
         4 . The method of  claim 1 , wherein the polar surface active lipid is obtained from a cellular or tissue source. 
     
     
         5 . The method of  claim 1 , wherein the polar surface active lipid is synthetically produced. 
     
     
         6 . The method of  claim 1 , wherein the plurality of amino acids are obtained from a cellular or tissue source. 
     
     
         7 . The method of  claim 1 , wherein the plurality of amino acids are synthetically produced. 
     
     
         8 . The method of  claim 1 , wherein the extracellular matrix compound is selected from the group consisting of glucosamine, a glycosaminoglycan, a collagen, cartilage, chondroitin sulfate, hyaluronic acid, hyaluronan mucopolysaccharides, a glycoprotein, and a proteoglycan. 
     
     
         9 . The method of  claim 1 , wherein the extracellular matrix compound is glucosamine. 
     
     
         10 . The method of  claim 1 , wherein the polar surface active lipid is selected from the group consisting of a lipid, a phospholipid, a glycolipid, a monoglyceride, a diglyceride and lipoprotein. 
     
     
         11 . The method of  claim 1 , wherein the composition is administered orally, topically or parenterally. 
     
     
         12 . The method of  claim 1 , wherein the at least one extracellular matrix compound, the at least one polar surface active lipid, and the at least one amino acid associate through a molecular bonding force. 
     
     
         13 . The method of  claim 1 , wherein said molecular bonding force is selected from the group consisting of hydrogen bonding, electrostatic, van der Waals and ionic. 
     
     
         14 . The method of  claim 1 , wherein the composition further comprises at least one of (a) a mineral; (b) a vitamin; (c) an antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; and (j) collagen. 
     
     
         15 . The method of  claim 1 , wherein the composition further comprises gamma amino butyric acid or L-carnitine. 
     
     
         16 . The method of  claim 1 , wherein the composition further comprises a medium chain, short chain fatty acids or lipoproteins. 
     
     
         17 . The method of  claim 1 , wherein the composition further comprises a fatty acid selected from the group consisting of linoleic acid, linolenic acid, vitellin, lipovitellin, phosphoprotein, cerebrosides and cephalin. 
     
     
         18 . The method of  claim 1 , wherein the damaged tissue is selected from the group consisting of tissues of mesenchymal origin, tissues of endodermal origin, tissues of mesodermal origin and tissues of ectodermal origin. 
     
     
         19 . The method of  claim 1 , wherein the damaged tissue is selected from the group consisting of skin, eye, liver, gastro-intestinal, kidney, cardio-vascular system, respiratory tract, endocrine, joint, musculoskeletal system, peripheral nervous system, central nervous system and lung. 
     
     
         20 . The method of  claim 19 , wherein the damaged tissue is skin. 
     
     
         21 . The method of  claim 19 , wherein the gastro-intestinal tissue is bowel tissue. 
     
     
         22 . The method of  claim 21 , wherein the bowel tissue is damaged from regional ileitis (Crohn's Disease), inflammatory bowel disease, ulcerative colitis, or mucous colitis. 
     
     
         23 . A method of treating damaged tissue, comprising: 1) identifying damaged tissue in a subject; 2) determining the molar ratio of amino acids in healthy tissue corresponding to the damaged tissue; and 3) administering to the subject a composition comprising: a) at least one extracellular matrix compound in an amount effective in the damaged tissue as anti-inflammatory and anti-neo-angiogenetic agent, b) at least one polar surface active lipid; and c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is substantially similar to the amino acid ratio of the healthy tissue sample, and wherein no more than 10% of the amino acids are in D-form. 
     
     
         24 . The method of  claim 23 , wherein the damaged tissue is selected from the group consisting of tissue of mesenchymal origin, tissue of endodermal origin, tissue of mesodermal origin and tissue of ectodermal origin. 
     
     
         25 . The method of  claim 23 , wherein the damaged tissue is selected from the group consisting of skin, eye, liver, gastro-intestinal, kidney, cardio-vascular system, respiratory tract, endocrine, joint, musculoskeletal system, peripheral nervous system, central nervous system and lung. 
     
     
         26 . A composition for treating a damaged tissue, comprising: a) at least one mucopolysaccharide extracellular matrix compound in an amount effective in the damaged tissue as anti-inflammatory and anti-neo-angiogenetic agent, b) at least one polar surface active lipid; and c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of an antibiotic comprising amino acids, and wherein no more than 10% of the amino acids are in D-form. 
     
     
         27 . The composition of  claim 26 , wherein the antibiotic is cyclosporin. 
     
     
         28 . A composition for treating a damaged tissue, comprising: a) at least one mucopolysaccharide extracellular matrix compound in an amount effective in the damaged tissue as anti-inflammatory and anti-neo-angiogenetic agent, b) at least one polar surface active lipid; and c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of fibrinogen, wherein no more than 10% of the amino acids are in D-form. 
     
     
         29 . A method of treating HIV infection, comprising administering an anabolic composition to a subject in need of such treatment, wherein the composition comprises: a) at least one extracellular matrix compound in an amount effective in the damaged tissue as anti-inflammatory and anti-neo-angiogenetic agent, b) at least one polar surface active lipid; and c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of human breast milk protein, and wherein no more than 10% of the amino acids are in D-form. 
     
     
         30 . A method of reducing the effects of aging, comprising administering an anabolic composition to a subject in need of such treatment, wherein the composition comprises: a) at least one extracellular matrix compound in an amount effective in the damaged tissue as anti-inflammatory and anti-neo-angiogenetic agent, b) at least one polar surface active lipid; and c) a plurality of amino acids having an alpha carbon, the amino acids being present at a molar ratio which is characteristic of human breast milk protein, and wherein no more than 10% of the amino acids are in D-form.